Q-Line Biotech Peer Comparison

NSE: QLINE

₹611.65

₹9.90 (1.65%)

As on 14-Oct-2026IST

Market cap

₹1,427 Cr

Revenue (TTM)

₹342 Cr

P/E Ratio

25.6

P/B Ratio

5.6

Div. Yield

0 %

Edit

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Market cap (₹ Cr)	1,427	16,079	331	311	187
Revenue (₹ Cr)	342	1,997	183	153	55
Net Profit (₹ Cr)	55.72	307.01	12.72	4.34	5.13
Net Margin (%)	16.04	14.56	6.90	2.70	9.22
RoE (%)	25.55	10.63	10.39	2.29	7.67
Price to Earnings	25.61	51.03	30.38	71.70	36.57
Price-To-Book	5.63	5.05	--	1.69	2.69

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Operating Revenue	341.74	1,875.26	--	146.96	55.13
Total Income	347.44	2,002.19	--	155.06	55.62
Total Expenditure	243.64	1,436.66	--	146.78	44.60
EBITDA	98.10	438.59	--	0.18	10.54
Depreciation	10.79	115.52	--	2.02	0.09
EBIT	87.31	323.08	--	-1.84	10.44
Interest	19.47	21.42	--	1.28	3.64
Other Income	5.70	126.93	--	8.10	0.49
Exceptional Items	-0.99	-6.80	--	--	--
Profit before Tax	72.55	427.47	--	4.98	7.29
Provision for Tax	16.83	106.74	--	2.90	2.16
Profit after Tax	55.72	320.73	--	2.08	5.13

Liabilities (₹ Cr)

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Shareholder's Funds	246.19	3,106.17	--	180.76	69.40
Minority Interest	--	43.07	--	--	0.18
Non-Current Liabilities	101.51	120.16	--	-0.92	1.26
Current Liabilities	209.92	666.53	--	13.78	10.50
Total Liabilities	558.69	3,951.60	--	196.16	82.27

Assets (₹ Cr)

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Non-Current Assets	213.57	1,903.19	--	78.94	8.03
Current Assets	344.06	2,032.74	--	114.68	73.30
Total Assets	558.69	3,951.60	--	196.16	82.27
Total Debt*	225.48	341.62	--	0.72	7.14
Net Current Assets	134.14	1,366.21	--	100.90	62.80
Contingent Liabilities	52.55	50.21	--	4.73	8.06

Cashflow (₹ Cr)

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Cash From Operating Activities	16.38	246.37	--	3.30	31.23
Cash Flow from Investing Activities	-29.42	-225.38	--	14.49	-4.45
Cash from Financing Activities	41.64	20.15	--	-19.56	-26.66
Net Cash Inflow / Outflow	28.60	41.14	--	-1.77	0.12

Ratios

Profitability Ratios

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
ROCE (%)	22.23	14.05	--	3.31	12.77
ROE (%)	25.55	10.94	--	1.11	7.67
ROA (%)	11.01	8.89	--	1.04	4.56
EBIT Margin (%)	30.37	30.16	--	5.63	19.99
Net Margin (%)	16.04	16.02	--	1.34	9.22
Cash Profit Margin (%)	18.40	23.12	--	2.57	9.46

Growth Ratios

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Revenue Growth (%)	9.13	12.30	--	34.02	-59.37
EBIT Growth (%)	40.81	3.80	--	69.11	-55.90
Net Profit Growth (%)	255.32	-5.27	--	145.86	-68.18
EPS Growth (%)	180.69	-4.88	--	157.91	-68.34
Book Value Growth (%)	29.61	12.14	--	-6.96	8.00

Valuation Ratios

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Price / Earnings	0.00	37.47	--	94.46	76.00
Price / Book Value	0.00	3.90	--	1.09	5.59
Dividend Yield (%)	--	0.29	--	0.00	0.00
EV/EBITDA	1.59	21.79	--	18.84	35.29
Market Cap (₹ Cr)	0.00	12,069.92	--	196.67	387.75

Solvency Ratios

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Debt to Equity	0.92	0.11	--	0.00	0.10
Short term debt to equity ratio	0.36	0.08	--	0.00	0.06
Current Ratio	1.64	3.05	--	8.32	6.98
Quick Ratio	1.19	2.40	--	4.88	6.73
Interest Coverage	4.73	20.96	--	4.88	3.00

Operating Efficiency Ratios

	Q-Line Biotech	Poly Medicure	QMS Medical	Nureca	Aprameya Engineering
Debtors to sales (%)	36.82	28.33	--	5.27	100.70
Asset Turnover	0.71	0.52	--	0.80	0.49
Receivable days	105.22	85.20	--	12.70	577.64
Inventory Days	93.48	69.58	--	100.27	32.62
Payable days	146.52	77.97	--	22.92	666.27
Cash Conversion Cycle	52.17	76.82	--	90.04	-56.01